Davidson, B. A., Squatrito, R., Duska, L. R., Havrilesky, L. J., Schwager, N., McCollum, M., … Secord, A. A. (2016). Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. In Journal of Clinical Oncology (Vol. 34, pp. TPS5601–TPS5601). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.tps5601

Davidson, Brittany Anne, Robert Squatrito, Linda R. Duska, Laura Jean Havrilesky, Nyssa Schwager, Michael McCollum, Sanja Arapovic, and Angeles Alvarez Secord. “Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.” In Journal of Clinical Oncology, 34:TPS5601–TPS5601. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps5601.

Davidson BA, Squatrito R, Duska LR, Havrilesky LJ, Schwager N, McCollum M, et al. Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS5601–TPS5601.

Davidson, Brittany Anne, et al. “Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. TPS5601–TPS5601. Crossref, doi:10.1200/jco.2016.34.15_suppl.tps5601.

Davidson BA, Squatrito R, Duska LR, Havrilesky LJ, Schwager N, McCollum M, Arapovic S, Secord AA. Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS5601–TPS5601.